151 related articles for article (PubMed ID: 16360812)
21. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.
Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ
Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934
[TBL] [Abstract][Full Text] [Related]
22. Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer.
Mahdi H; Gockley A; Esselen K; Marquard J; Nutter B; Yang B; Hinchcliff E; Horowitz N; Rose PG
Gynecol Oncol; 2015 Dec; 139(3):407-12. PubMed ID: 26210778
[TBL] [Abstract][Full Text] [Related]
23. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
Rzepecka IK; Szafron L; Stys A; Bujko M; Plisiecka-Halasa J; Madry R; Osuch B; Markowska J; Bidzinski M; Kupryjanczyk J
Cancer Genet; 2012 Mar; 205(3):94-100. PubMed ID: 22469508
[TBL] [Abstract][Full Text] [Related]
24. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
Stefansson OA; Villanueva A; Vidal A; Martí L; Esteller M
Epigenetics; 2012 Nov; 7(11):1225-9. PubMed ID: 23069641
[TBL] [Abstract][Full Text] [Related]
25. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
[TBL] [Abstract][Full Text] [Related]
26. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
27.
Kraya AA; Maxwell KN; Eiva MA; Wubbenhorst B; Pluta J; Feldman M; Nayak A; Powell DJ; Domchek SM; Vonderheide RH; Nathanson KL
JCO Precis Oncol; 2022 Feb; 6():e2100159. PubMed ID: 35201851
[TBL] [Abstract][Full Text] [Related]
28. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
Gynecol Oncol; 2008 Feb; 108(2):433-7. PubMed ID: 17997147
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
Chan KY; Ozçelik H; Cheung AN; Ngan HY; Khoo US
Cancer Res; 2002 Jul; 62(14):4151-6. PubMed ID: 12124354
[TBL] [Abstract][Full Text] [Related]
30. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
Rubin SC; Benjamin I; Behbakht K; Takahashi H; Morgan MA; LiVolsi VA; Berchuck A; Muto MG; Garber JE; Weber BL; Lynch HT; Boyd J
N Engl J Med; 1996 Nov; 335(19):1413-6. PubMed ID: 8875917
[TBL] [Abstract][Full Text] [Related]
31. Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers.
Bijron JG; van der Groep P; van Dorst EB; Seeber LM; Sie-Go DM; Verheijen RH; van Diest PJ
Endocr Relat Cancer; 2012 Feb; 19(1):69-81. PubMed ID: 22143498
[TBL] [Abstract][Full Text] [Related]
32. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
[TBL] [Abstract][Full Text] [Related]
33. Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian Cancer.
Blanc-Durand F; Tang R; Pommier M; Nashvi M; Cotteret S; Genestie C; Le Formal A; Pautier P; Michels J; Kfoury M; Hervé R; Mengue S; Wafo E; Elies A; Miailhe G; Uzan J; Rouleau E; Leary A
Clin Cancer Res; 2023 Aug; 29(16):3124-3129. PubMed ID: 37067532
[TBL] [Abstract][Full Text] [Related]
34. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors.
Ben David Y; Chetrit A; Hirsh-Yechezkel G; Friedman E; Beck BD; Beller U; Ben-Baruch G; Fishman A; Levavi H; Lubin F; Menczer J; Piura B; Struewing JP; Modan B;
J Clin Oncol; 2002 Jan; 20(2):463-6. PubMed ID: 11786575
[TBL] [Abstract][Full Text] [Related]
35. Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both.
de la Hoya M; Fernández JM; Tosar A; Godino J; Sánchez de Abajo A; Vidart JA; Pérez-Segura P; Díaz-Rubio E; Caldés T
JAMA; 2003 Aug; 290(7):929-31. PubMed ID: 12928470
[TBL] [Abstract][Full Text] [Related]
36. Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation.
de Jong VMT; Pruntel R; Steenbruggen TG; Bleeker FE; Nederlof P; Hogervorst FBL; Linn SC
Fam Cancer; 2023 Apr; 22(2):151-154. PubMed ID: 36112334
[TBL] [Abstract][Full Text] [Related]
37. BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study.
Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Tumour Biol; 2014 May; 35(5):4277-84. PubMed ID: 24385383
[TBL] [Abstract][Full Text] [Related]
38. Frequency of BRCA1 dysfunction in ovarian cancer.
Geisler JP; Hatterman-Zogg MA; Rathe JA; Buller RE
J Natl Cancer Inst; 2002 Jan; 94(1):61-7. PubMed ID: 11773283
[TBL] [Abstract][Full Text] [Related]
39. Hereditary ovarian cancer.
Prat J; Ribé A; Gallardo A
Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
[TBL] [Abstract][Full Text] [Related]
40. [Management of hereditary ovarian cancer].
Joó JG; Ládi S; Nagy BZ; Langmár Z
Orv Hetil; 2011 Oct; 152(40):1596-608. PubMed ID: 21945869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]